Expanding ADC Target Applications Through Innovative Linker Payload Chemistry Releasing Payload Without Internalization

• Utilizing novel linker chemistry to circumvent the need for ADC internalization for payload release 
• Applying novel linker payload technology to unlock development against previously inaccessible ADC targets  
• Demonstrating novel target accessibility through preclinical efficacy and safety data of anti-VEGF avastin ADC YL242

Speakers:

Jiaqiang Cai

Co-founder and CSO and Co-Chief Executive Officer

Medilink Therapeutics